← Back to Patent Explorer
EP0227619A2 Expired / Lapsed EP ⏱️ 0.0 years remaining

New protein and its use

Assignee: Kabigen AB
•
Filing: 1986-12-02
•
Granted: —
•
Expires: 2006-12-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Protein comprising at the N-terminal thereof the amino acid sequence: NH₂-Thr¹-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala¹⁰-Leu-Gln-Phe-Val-­Cys-Gly-Asp-Arg-Gly-Phe²⁰-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-R wherein R is an amino acid sequence such that the overall appa­rent molecular weight of the protein is about 7000; method of stimulating brain cell growth; composition for therapeutic or diagnostic use; and a method for diagnosing the presence of brain cell growth factor.

Inventors

  • 👤 Vicki Rubian Sara

Bibliographic Details

Application Number —
Jurisdiction EP
Data Source google_patents
Last Synchronized 2026-11-07 13:44
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/65; A; A61; A61P; A61P25/00; A61K; A61K38/00

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 31 words
Protein comprising at the N-terminal thereof the amino acid sequence: NH₂-Thr¹-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala¹⁰-Leu-Gln-Phe-Val-­Cys-Gly-Asp-Arg-Gly-Phe²⁰-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-R wherein R is an amino acid sequence such that the overall appa­rent molecular weight of the protein is about 7000.
Claim 2
Dependent Claim 31 words
Protein comprising at the N-terminal thereof the amino acid sequence: NH₂-Thr¹-Leu-Cys-Gly-Ala-Glu-Leu-Val-Asp-Ala¹⁰-Leu-Gln-Phe-Val-­Cys-Gly-Asp-Arg-Gly-Phe²⁰-Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-R wherein R is an amino acid sequence such that the overall appa­rent molecular weight of the protein is about 7000.
Claim 3
Dependent Claim 29 words
Protein according to claim 1, wherein R is such that the overall composition of the protein corresponds to that of IGF-1 excluding the three N-terminal amino acid residues the­reof.
Claim 4
Dependent Claim 29 words
Protein according to claim 2, wherein R is such that the overall structure of the protein corresponds to that of IGF-1 excluding the three N-terminal amino acid residues there­of.
Claim 5
Dependent Claim 31 words
A method of stimulating neural tissue growth in mammals including man, comprising administering an effective amount of the protein of claim 1, 2 or 3 to a mammal subject to treatment.
Claim 6
Dependent Claim 32 words
A composition for therapeutic or diagnostic use com­prising in combination an active amount of the protein of any of claims 1 to 3 in combination with a nontoxic and noninter­fering carrier therefor.
Claim 7
Dependent Claim 41 words
A method for diagnosing the presence of neural tissue growth factor in physiological fluids and tissues using the immunological interaction between antibodies generated by the protein of claim 1 and antigen comprised in a fluid or tissue sample subject to diagnosis.
Claim 8
Dependent Claim 50 words
A method according to claim 6 comprising the steps: a) generating antibodies to the protein of claim 1; b) recording inhibition of interaction between anti­bodies obtained under step a) and a labelled protein according to claim 1 by adding varying amounts of a fluid or tissue samp­le subject to test.
Claim 9
Dependent Claim 11 words
A method according to claim 4 applied to brain cell growth.
Claim 10
Dependent Claim 11 words
A method according to claim 6 applied to brain cell growth.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag